Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
作者： Jaafar Bennouna , Javier Sastre , Dirk Arnold , Pia Österlund , Richard Greil
DOI: 10.1016/S1470-2045(12)70477-1
关键词: Colorectal cancer 、 Bevacizumab 、 Chemotherapy 、 Oxaliplatin 、 Phases of clinical research 、 Regimen 、 Irinotecan 、 Standard treatment 、 Medicine 、 Oncology 、 Internal medicine
摘要: … An additional secondary endpoint was on-treatment progression-free survival, defined as … while switching chemotherapy from the first and second lines in colorectal cancer has clinical …
els-cdn.com参考文章(26)
Sam Mesiano, Napoleone Ferrara, Robert B. Jaffe, Role of Vascular Endothelial Growth Factor in Ovarian Cancer The American Journal of Pathology. ,vol. 153, pp. 1249- 1256 ,(1998) , 10.1016/S0002-9440(10)65669-6
Howard R. Mellor, Richard Callaghan, Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology. ,vol. 81, pp. 275- 300 ,(2008) , 10.1159/000115967
Stuart J. Pocock, Richard Simon, Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial Biometrics. ,vol. 31, pp. 103- 115 ,(1975) , 10.2307/2529712
Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland, Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 60- 65 ,(2003) , 10.1200/JCO.2003.10.066
Gabriele Bergers, Douglas Hanahan, Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer. ,vol. 8, pp. 592- 603 ,(2008) , 10.1038/NRC2442
Giannoula Klement, Sylvain Baruchel, Janusz Rak, Shan Man, Katherine Clark, Daniel J. Hicklin, Peter Bohlen, Robert S. Kerbel, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity Journal of Clinical Investigation. ,vol. 105, pp. 2827- 2827 ,(2000) , 10.1172/JCI8829
Bruce J. Giantonio, Goldie–Coldman and bevacizumab beyond disease progression Nature Reviews Clinical Oncology. ,vol. 6, pp. 311- 312 ,(2009) , 10.1038/NRCLINONC.2009.66
OSTAP MELNYK, MICHAEL ZIMMERMAN, K. JIN KIM, MARC SHUMAN, NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODEL The Journal of Urology. ,vol. 161, pp. 960- 963 ,(1999) , 10.1016/S0022-5347(01)61829-9
Pi-Chun Li, Han-Chung Wu, Proteins Expressed on Tumor Endothelial Cells as Potential Targets for Anti-Angiogenic Therapy Journal of Cancer Molecules 4. ,vol. 4, pp. 17- 22 ,(2008) , 10.29685/JCM.200804.0003
Axel Grothey, Mary M. Sugrue, David M. Purdie, Wei Dong, Daniel Sargent, Eric Hedrick, Mark Kozloff, Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) Journal of Clinical Oncology. ,vol. 26, pp. 5326- 5334 ,(2008) , 10.1200/JCO.2008.16.3212